Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mohamed Amine Bani1, Sophie Moog2, Voichita Suciu3

  • 1Département de biologie et pathologie médicales, laboratoire de pathologie morphologique, Gustave Roussy Cancer Campus, F-94805 Villejuif, France; Université de Paris-Saclay, Gustave Roussy Cancer Centre, Inserm US23, CNRS UMS3655, AMMICa, F-94805 Villejuif, France.

Bulletin Du Cancer
|November 6, 2024
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic arterial embolization procedures in neuroendocrine tumors with carcinoid heart disease: a retrospective single-center study on safety and feasibility.

Endocrine-related cancer·2026
Same author

[Mucinous carcinomas across organs: Definitions, profiles, diagnostic pitfalls and practical implications for pathologists].

Annales de pathologie·2026
Same author

[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

The Lancet. Oncology·2026
Same author

Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey.

European journal of endocrinology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort study.

The lancet. Diabetes & endocrinology·2026

Recent updates to thyroid classifications (WHO 2022, Bethesda 2023) and molecular findings enhance thyroid cancer prognosis and targeted therapy development. These advances offer practical insights for clinicians managing thyroid diseases.

Area of Science:

  • Endocrinology
  • Pathology
  • Oncology

Background:

  • The 5th edition of the World Health Organization (WHO) Classification of Endocrine Tumors (2022) and the 3rd edition of the Bethesda System for Thyroid Cytopathology (2023) represent significant updates in thyroid pathology.
  • Advances in molecular biology, particularly next-generation sequencing, have greatly expanded our understanding of thyroid cancer genomics and mechanisms.

Purpose of the Study:

  • To review the key innovations in the WHO 2022 and Bethesda 2023 classifications for thyroid tumors.
  • To discuss recent molecular biology findings in thyroid cancer.
  • To highlight the clinical implications of these advancements for healthcare professionals.

Main Methods:

  • Literature review of the latest WHO and Bethesda system publications.
Keywords:
Bethesda systemClassification OMSCytopathologie thyroïdiennePathologie thyroïdienneSystème BethesdaThyroid cytopathologyThyroid pathologyThyroid tumorsTumeurs thyroïdiennesWHO classification

Related Experiment Videos

  • Synthesis of current knowledge on thyroid cancer genomics and molecular testing.
  • Analysis of translational research impacting clinical practice.

    • Main Results:

    • The WHO 2022 and Bethesda 2023 classifications introduce refined diagnostic criteria and terminology for thyroid neoplasms.
    • Molecular profiling is increasingly integrated into thyroid cancer diagnosis, prognosis, and treatment selection.
    • New targeted therapies are emerging based on specific molecular alterations identified in thyroid cancers.

    Conclusions:

    • The updated classifications and molecular insights provide a more precise framework for diagnosing and managing thyroid cancer.
    • Integration of molecular testing is crucial for personalized treatment strategies and improved patient outcomes.
    • Clinicians must stay abreast of these rapidly evolving fields to optimize patient care in thyroid pathology.